Kaitlyn Alleman, Molly Buchanan, Laura Bute, Nathan Holthaus, Kathleen McCaslin, Katie Parker
Download Project (877 KB)
Glioma is a deadly brain cancer, and current treatments have been unsuccessful in prolonging life more than a few months. In an effort to discover better treatments with more direct targets, we are conducting a chemical screen using Tyrosine Kinase inhibitors (Selleck Biochem). Promising results of such inhibitors will suppress the progression of glioma by (a) inhibiting the underlying molecular pathways activated in glioma, or (b) prevent rapid proliferation of the glia and other cells that encompass the glioma tumor. We have induced glioma in Drosophila by activating two of the most common oncogenic pathways, PI3K and Ras/MAPK. The activation of these pathways results in an enlarged brain from an increase in stem cells and their glia and neural progeny. These tumors cause the larvae to enter a prolonged larval phase, and eventually kill the organism. During our screen, larvae are added to food in their early third instar phase (72h old). The food is infused with 10 or 300uM chemicals in DMSO and where we then see effects on glioma growth, and survival in mature third instar stage (120h old). Using these metrics, here we present data from our screen on promising drugs from this academic year’s testing focusing on drugs E7, E9, and E11. Once we identify potential glioma inhibitors in the primary screens, we will validate them in secondary screens.
Primary Advisor's Department
Stander Symposium project, College of Arts and Sciences
United Nations Sustainable Development Goals
Good Health and Well-Being
"Effects of Tyrosine Kinase Inhibitor Drugs on Glioma" (2020). Stander Symposium Projects. 2011.